Expert Interview
Discussing the potential of Baxdrostat(CIN-107) in resistant hypertension in light of the recent top line results from the Phase 2 HALO trial.
Ticker(s): CINCInstitution: VA Medical Center
- received his medical degree from Government Medical College Patiala and has been in practice for 36 years specializing in Endocrinology and Diabetes & Metabolism
- manages treatment for 75 patients with resistant hypertension
- familiar with Baxdrostat (CIN-107) and KBP-5074 (Ocedurenone)
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
